Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $357000.0.

  • Champions Oncology's Depreciation & Amortization (CF) fell 1052.63% to $357000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $1.5 million, marking a year-over-year decrease of 1562.15%. This contributed to the annual value of $1.6 million for FY2025, which is 1215.85% down from last year.
  • Per Champions Oncology's latest filing, its Depreciation & Amortization (CF) stood at $357000.0 for Q4 2025, which was down 1052.63% from $358000.0 recorded in Q3 2025.
  • Champions Oncology's 5-year Depreciation & Amortization (CF) high stood at $583000.0 for Q2 2023, and its period low was $297000.0 during Q1 2021.
  • In the last 5 years, Champions Oncology's Depreciation & Amortization (CF) had a median value of $422000.0 in 2023 and averaged $434750.0.
  • As far as peak fluctuations go, Champions Oncology's Depreciation & Amortization (CF) soared by 8745.87% in 2022, and later plummeted by 2161.23% in 2024.
  • Champions Oncology's Depreciation & Amortization (CF) (Quarter) stood at $346000.0 in 2021, then soared by 61.85% to $560000.0 in 2022, then dropped by 13.57% to $484000.0 in 2023, then dropped by 17.56% to $399000.0 in 2024, then dropped by 10.53% to $357000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $357000.0 for Q4 2025, versus $358000.0 for Q3 2025 and $394000.0 for Q2 2025.